{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:35:09Z","timestamp":1784673309846,"version":"3.55.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI159182"],"award-info":[{"award-number":["R01AI159182"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jbc.2026.111210","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:02:58Z","timestamp":1769616178000},"page":"111210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Engineered IgA-Fc fusion protein with bioactive nanobody neutralizes SARS-CoV-2 variants with mucosal delivery potential"],"prefix":"10.1016","volume":"302","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2690","authenticated-orcid":false,"given":"Rachel M.","family":"Golonka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Intravaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala M.","family":"Shaqra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiachra","family":"Humphries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese","family":"Kurt-Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-8339","authenticated-orcid":false,"given":"Lisa A.","family":"Cavacini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2026.111210_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543784.2022.2030310","article-title":"Monoclonal antibody therapies in the management of SARS-CoV-2 infection","volume":"31","author":"Miguez-Rey","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jbc.2026.111210_bib2","doi-asserted-by":"crossref","first-page":"e163471","DOI":"10.1172\/jci.insight.163471","article-title":"Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses","volume":"7","author":"Ramirez","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jbc.2026.111210_bib3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.jbc.2026.111210_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s43856-024-00523-w","article-title":"Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report","volume":"4","author":"Sam","year":"2024","journal-title":"Commun. Med. (Lond)"},{"key":"10.1016\/j.jbc.2026.111210_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jbc.2026.111210_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/mi.2007.6","article-title":"The immune geography of IgA induction and function","volume":"1","author":"Macpherson","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jbc.2026.111210_bib7","article-title":"Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers","volume":"47","author":"Gao","year":"2024","journal-title":"Semin. Immunopathol"},{"key":"10.1016\/j.jbc.2026.111210_bib8","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00018-018-2976-8","article-title":"The inflammatory function of human IgA","volume":"76","author":"Hansen","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.jbc.2026.111210_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105823","article-title":"Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses","volume":"223","author":"Sinha","year":"2024","journal-title":"Antivir. Res"},{"key":"10.1016\/j.jbc.2026.111210_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2023.199294","article-title":"Rapid increase in salivary IgA and broad recognition of spike protein following SARS-CoV-2 vaccination","volume":"339","author":"Ota","year":"2024","journal-title":"Virus Res."},{"key":"10.1016\/j.jbc.2026.111210_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44989-5","article-title":"Utility of nasal swabs for assessing mucosal immune responses towards SARS-CoV-2","volume":"13","author":"Roubidoux","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2026.111210_bib12","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/imcb.12682","article-title":"Serological assays to measure dimeric IgA antibodies in SARS-CoV-2 infections","volume":"101","author":"Wei","year":"2023","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jbc.2026.111210_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1346749","article-title":"Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum","volume":"15","author":"Bladh","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.111210_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315354120","article-title":"Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages","volume":"121","author":"Marcotte","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.111210_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd2223","article-title":"IgA dominates the early neutralizing antibody response to SARS-CoV-2","volume":"13","author":"Sterlin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2026.111210_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41467-024-45171-9","article-title":"A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity","volume":"15","author":"de Campos-Mata","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib17","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1038\/s41467-020-18058-8","article-title":"A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction","volume":"11","author":"Ejemel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/mi.2009.89","article-title":"HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis","volume":"2","author":"Tudor","year":"2009","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.jbc.2026.111210_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01552-17","article-title":"HIV-1-Specific IgA monoclonal antibodies from an HIV-1 vaccinee mediate galactosylceramide blocking and phagocytosis","volume":"92","author":"Wills","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/jvi.69.2.1339-1343.1995","article-title":"Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies","volume":"69","author":"Mazanec","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib21","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1128\/JVI.00979-13","article-title":"Recombinant IgA is sufficient to prevent influenza virus transmission in Guinea pigs","volume":"87","author":"Seibert","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib22","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1128\/JVI.00768-11","article-title":"Matrix protein-specific IgA antibody inhibits measles virus replication by intracellular neutralization","volume":"85","author":"Zhou","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.jbc.2026.111210_bib24","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.2174\/0929867324666170113112759","article-title":"Fc-fusion proteins in therapy: an updated view","volume":"24","author":"Jafari","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jbc.2026.111210_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/imr.13385","article-title":"Nanobody-based heavy chain antibodies and chimeric antibodies","volume":"328","author":"Koch-Nolte","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jbc.2026.111210_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009103","article-title":"The CH1alpha domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals","volume":"16","author":"Khamassi","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2026.111210_bib27","article-title":"Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.111210_bib28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1467-7652.2005.00171.x","article-title":"HIV-1 p24-immunoglobulin fusion molecule: a new strategy for plant-based protein production","volume":"4","author":"Obregon","year":"2006","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.jbc.2026.111210_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017665","article-title":"Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules","volume":"6","author":"Hultberg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.111210_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.copbio.2019.11.006","article-title":"Simplified monomeric VHH-Fc antibodies provide new opportunities for passive immunization","volume":"61","author":"De Greve","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jbc.2026.111210_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jbc.2026.111210_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107085","article-title":"A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants","volume":"26","author":"Modhiran","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jbc.2026.111210_bib33","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1038\/s41598-021-81895-0","article-title":"Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design","volume":"11","author":"Amcheslavsky","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2026.111210_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib35","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn1413","article-title":"Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity","volume":"14","author":"Hartwell","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jbc.2026.111210_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175233","article-title":"Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2","volume":"135","author":"Lin","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbc.2026.111210_bib37","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-021-03207-w","article-title":"Evolution of antibody immunity to SARS-CoV-2","volume":"591","author":"Gaebler","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.111210_bib38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/infdis\/jiad385","article-title":"Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition","volume":"229","author":"Froberg","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jbc.2026.111210_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110393","article-title":"B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination","volume":"38","author":"Kotagiri","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2026.111210_bib40","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1002\/jmv.28034","article-title":"Distinct immune responses in the early phase to natural SARS-CoV-2 infection or vaccination","volume":"94","author":"Peng","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib41","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1093\/infdis\/jiad525","article-title":"Variant-specific IgA protects against Omicron infection","volume":"230","author":"Goh","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jbc.2026.111210_bib42","article-title":"Characteristics of Vaccine- and infection-induced systemic IgA Anti-SARS-CoV-2 spike responses","volume":"11","author":"Norton","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jbc.2026.111210_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.07.024","article-title":"Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: a prospective cohort study","volume":"42","author":"Korchinski","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.111210_bib44","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/INF.0000000000004291","article-title":"Specific IgA, but not IgG, in human milk from COVID-19-Infected mothers neutralizes SARS-CoV-2","volume":"43","author":"Macchiaverni","year":"2024","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.jbc.2026.111210_bib45","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1089\/aid.1998.14.1617","article-title":"Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein","volume":"14","author":"Challita-Eid","year":"1998","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jbc.2026.111210_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576012","article-title":"A highly expressing, soluble, and stable plant-made IgG fusion vaccine strategy enhances antigen immunogenicity in mice without adjuvant","volume":"11","author":"Diamos","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2026.111210_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011770","article-title":"EDIII-Fc induces protective immune responses against the Zika virus in mice and rhesus macaque","volume":"17","author":"Su","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jbc.2026.111210_bib48","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/aid.2006.22.477","article-title":"An immunoglobulin fusion protein based on the gp120-CD4 receptor complex potently inhibits human immunodeficiency virus type 1 in vitro","volume":"22","author":"Vu","year":"2006","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jbc.2026.111210_bib49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2019.02.017","article-title":"A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection","volume":"165","author":"Zhang","year":"2019","journal-title":"Antivir. Res"},{"key":"10.1016\/j.jbc.2026.111210_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pep.2018.08.012","article-title":"Half-life extension of porcine interferon-alpha by fusion to the IgG-binding domain of streptococcal G protein","volume":"153","author":"Zong","year":"2019","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbc.2026.111210_bib51","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1016\/j.vaccine.2021.09.077","article-title":"Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452","volume":"39","author":"Alleva","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jbc.2026.111210_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121525","article-title":"Enhancement of immunogenicity and neutralizing responses against SARS-CoV-2 spike protein using the Fc fusion fragment","volume":"320","author":"Ehteshaminia","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.jbc.2026.111210_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.686421","article-title":"A V(H)H-Fc fusion targeted to the Chloroplast thylakoid lumen assembles and neutralizes enterohemorrhagic E. coli O157:H7","volume":"12","author":"Chin-Fatt","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.jbc.2026.111210_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.651262","article-title":"A rationally designed bovine IgA Fc scaffold enhances in planta accumulation of a V(H)H-Fc fusion without compromising binding to enterohemorrhagic E. coli","volume":"12","author":"Chin-Fatt","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.jbc.2026.111210_bib55","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41467-023-36106-x","article-title":"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib56","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021107985","article-title":"Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies","volume":"40","author":"Guttler","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.jbc.2026.111210_bib57","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib58","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.3390\/cells11213355","article-title":"Screening, expression, and identification of nanobody against SARS-CoV-2 spike protein","volume":"11","author":"Su","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jbc.2026.111210_bib59","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jbc.2026.111210_bib60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","article-title":"Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants","volume":"595","author":"Xu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.111210_bib61","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.89423.3","article-title":"Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus","volume":"12","author":"Ketaren","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.jbc.2026.111210_bib62","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2026.111210_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/978-3-319-72077-7_3","article-title":"Naive human antibody libraries for infectious diseases","volume":"1053","author":"Chan","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.jbc.2026.111210_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mco2.60","article-title":"A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential","volume":"2","author":"Gai","year":"2021","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.jbc.2026.111210_bib65","doi-asserted-by":"crossref","DOI":"10.3390\/v15061252","article-title":"Neutralizing and enhancing epitopes of the SARS-CoV-2 receptor-binding domain (RBD) identified by nanobodies","volume":"15","author":"Kaewchim","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jbc.2026.111210_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02438-20","article-title":"Potent neutralization of SARS-CoV-2 by hetero-bivalent alpaca nanobodies targeting the Spike receptor-binding domain","volume":"95","author":"Ma","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.jbc.2026.111210_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272364","article-title":"A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike","volume":"17","author":"Fu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.111210_bib68","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1958663","article-title":"Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies","volume":"13","author":"Stefan","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.jbc.2026.111210_bib69","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12951-022-01619-y","article-title":"A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode","volume":"20","author":"Zhao","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jbc.2026.111210_bib70","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202202099RR","article-title":"Identification of nurse shark V(NAR) single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2","volume":"37","author":"Buffington","year":"2023","journal-title":"FASEB J."},{"key":"10.1016\/j.jbc.2026.111210_bib71","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1038\/s41467-024-48735-x","article-title":"Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire","volume":"15","author":"Eden","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/protein\/gzn059","article-title":"Sequence determinants of protein aggregation in human VH domains","volume":"22","author":"Dudgeon","year":"2009","journal-title":"Protein Eng. Des. Sel"},{"key":"10.1016\/j.jbc.2026.111210_bib73","first-page":"531","article-title":"Protein identification and analysis tools in the ExPASy server","volume":"112","author":"Wilkins","year":"1999","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jbc.2026.111210_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2047144","article-title":"Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19","volume":"14","author":"Esparza","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.jbc.2026.111210_bib75","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12951-024-02345-3","article-title":"Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jbc.2026.111210_bib76","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","article-title":"Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization","volume":"624","author":"Ye","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.111210_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","article-title":"Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2","volume":"17","author":"Bracken","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2026.111210_bib78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ymthe.2024.01.025","article-title":"Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2","volume":"32","author":"Goritzer","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbc.2026.111210_bib79","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41467-021-27610-z","article-title":"A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo","volume":"13","author":"Hanke","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2026.111210_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41421-022-00497-w","article-title":"A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.jbc.2026.111210_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2026.111210_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011804","article-title":"Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization","volume":"19","author":"Yang","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2026.111210_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126817","article-title":"An engineered bispecific nanobody in tetrameric secretory IgA format confers broad neutralization against SARS-CoV-1&2 and most variants","volume":"253","author":"Zeng","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jbc.2026.111210_bib84","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2245921","article-title":"SARS-CoV-2 hijacks neutralizing dimeric IgA for nasal infection and injury in Syrian hamsters(1)","volume":"12","author":"Zhou","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.jbc.2026.111210_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006529","article-title":"A versatile viral system for expression and depletion of proteins in mammalian cells","volume":"4","author":"Campeau","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2026.111210_bib86","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","article-title":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice","volume":"589","author":"Zheng","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2026.111210_bib87","article-title":"Protein complex prediction with AlphaFold-Multimer","author":"Evans","year":"2022","journal-title":"bioRxiv"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925826000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:22:43Z","timestamp":1776381763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925826000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":87,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0021925826000803"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2026.111210","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered IgA-Fc fusion protein with bioactive nanobody neutralizes SARS-CoV-2 variants with mucosal delivery potential","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2026.111210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"111210"}}